New FDA Approved Drug Combo Offers Hope For Patients
Dec 18, 2025 · Understanding HER+ Breast Cancer A new FDA-approved treatment for HER2-positive metastatic breast cancer—trastuzumab deruxtecan (Enhertu) in combination with pertuzumab …
FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer
Dec 15, 2025 · The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.
T-DXd Wins First-Line Indication for HER2+ Breast Cancer
Dec 16, 2025 · FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or metastatic HER2-positive breast cancer.
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for ...
On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of ...
FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced …
Dec 15, 2025 · The FDA approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu; Daiichi Sankyo, Inc., AstraZeneca) in combination with pertuzumab (Perjeta; Genentech) for the first-line treatment of …
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic …
Dec 15, 2025 · The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.
Enhertu plus pertuzumab approved in the US as first new treatment in …
Dec 15, 2025 · AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with …
Dana-Farber Research Supports FDA Approval of T-DXd Plus …
Dec 15, 2025 · The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
Adding Tukysa Delays Growth of Metastatic HER2+ Breast Cancer
4 days ago · The standard first treatment people receive for metastatic HER2-positive breast cancer is taxane chemotherapy, along with two anti-HER2 medicines: Herceptin (chemical name: …
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
Dec 15, 2025 · The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or …